Therapeutic agents currently employed against Covid-19: an effort to control the pandemic
| Autor: | Iván Antonio García-Montalvo, Diana Matías-Pérez, Marco Antonio Sánchez-Medina, Alma Dolores Pérez-Santiago |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
business.industry
viruses Ribavirin Biochemistry (medical) Clinical Biochemistry virus diseases Lopinavir Hydroxychloroquine Disease medicine.disease_cause Biochemistry chemistry.chemical_compound Nelfinavir Immune system Tocilizumab chemistry Immunology medicine business Molecular Biology medicine.drug Coronavirus |
| Zdroj: | Turkish Journal of Biochemistry. 45:651-658 |
| ISSN: | 1303-829X 0250-4685 |
| DOI: | 10.1515/tjb-2020-0310 |
| Popis: | The disease caused by the new coronavirus (COVID-19) is characterized by fever and cough, in addition to affecting the lower respiratory tract and being associated with age, comorbidities and a weakened immune system. Lymphopenias occur in severe cases and an excessive production of inflammatory cytokines, which would explain the role of the hyperinflammatory response in the pathogenesis of COVID-19. In the absence of treatment for this virus, there is an urgent need to find alternative methods to control the spread of the disease, so we have conducted an online search for all treatment options related to coronavirus infections, as well as some infections due to viruses, general treatments, specific coronavirus treatments and antiviral treatments should be useful in the fight against COVID-19, the therapeutic agents evaluated included chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, ribavirin, interferons, nelfinavir, ivermectin, monoclonal antibodies and convalescent plasma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|